Sanjay Chandriani

Company: Maze Therapeutics

Job title: Director, Research and Development

Seminars:

Developing a Novel ATXN2-Targeting AAV Gene Therapy Treatment for Amyotrophic Lateral Sclerosis 11:00 am

Using human genetics, bioinformatics, and functional screens to identify a potent miRNA payload and an inert stuffer sequence Demonstrating preclinical efficacy in disease models of ALS Evaluating pharmacology, biodistribution in nonhuman primates in preparation for IND-enabling studiesRead more

day: Clinical Stream Day 1 AM